What period does MindMaze Therapeutics’ announcement cover?

The announcement was made on October 14, 2026, and covers a retrospective, multi-site quality improvement programme involving eight weeks of home training using MindMotion GO, with an optional four-week extension and periodic therapist supervision. The findings were presented yesterday at the American Congress of Rehabilitation Medicine in Washington, DC.

How many rehabilitation episodes and participants were included in MindMaze Therapeutics’ programme?

The programme evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke. It was conducted across four Vibra Healthcare outpatient sites and did not include a control group.

How much home-based training did participants complete independently in MindMaze Therapeutics’ programme?

Participants completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The announcement also states that 84% of active training was completed independently without direct therapist supervision.

What were the home-training completion and satisfaction results reported by MindMaze Therapeutics?

MindMaze Therapeutics reported that 92.7% of participants successfully completed home setup and 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive.

What functional improvements did MindMaze Therapeutics report from the home-based rehabilitation programme?

Statistically significant pre–post improvements were observed among participants with available paired assessments in independence, balance, cognition and mobility. The reported changes were +10.4 points on the Barthel Index, +10.5 points on the Berg Balance Scale, +3.4 points on SLUMS and −8.8 seconds on the Timed Up and Go test.

What limitations did MindMaze Therapeutics’ rehabilitation programme have?

The programme was retrospective and did not include a control group. Its comparison with usual outpatient therapy alone was based on published assumptions for active practice during usual care, and the functional outcome findings applied to participants with available paired assessments.

What does MindMaze Therapeutics say about the upcoming MindMotion Lite launch?

MindMaze Therapeutics said MindMotion Lite is expected by year-end 2026. The recently announced tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements.

How is MindMotion Lite intended to support home rehabilitation, according to MindMaze Therapeutics?

MindMaze Therapeutics said MindMotion Lite is designed to simplify home deployment and support broader adoption by healthcare providers. The company linked the planned solution to extending high-dose, high-intensity neurorehabilitation into patients’ homes.

What does MindMaze Therapeutics do and how does its platform work?

MindMaze Therapeutics provides scalable, precision neurotherapeutics across acute hospital care, outpatient treatment and home-based therapy. The company says it integrates advanced software, proprietary sensors and AI-driven data analytics, with products designed for stroke, Parkinson’s disease and other neurological disorders.

Where do MindMaze Therapeutics shares trade and what is the ticker symbol?

MindMaze Therapeutics identifies its shares as trading on SIX under the ticker symbol MMTX.

What did MindMaze Therapeutics’ CEO say about the home-based rehabilitation results?

Zach Henderson, CEO of MindMaze Therapeutics, said the results demonstrate that the company’s high-dose, high-intensity therapy can extend into the home to address a gap in care after patients leave the clinic. He also said the findings and the upcoming MindMotion Lite tablet-based solution would help make high-quality neurotherapeutics more accessible.

Where can investors find the full MindMaze Therapeutics rehabilitation programme poster?

MindMaze Therapeutics said the full poster, titled “High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program”, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Reports Home-Rehabilitation Findings as MindMotion Lite Is Expected by Year-End 2026

Published Wednesday, 14 October 2026, 05:00 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Operational update
Published: Wednesday, 14 October 2026, 05:00 AM
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period
Active training per week	174 minutes	per week
Total motor-training dose	a median factor of 3.0	Not stated
Satisfaction ratings were positive	83.8%	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Video summary 1 minute 13 seconds

The video covers the same ground as the plain English summary below.

Announcement Summary

MindMaze Therapeutics (SIX: MMTX) announced new real-world evidence from a multi-site home-based rehabilitation program with Vibra Healthcare, including training and functional results.

The findings were presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC.
The retrospective program evaluated 177 rehabilitation episodes involving 172 adults across four Vibra Healthcare outpatient sites without a control group.
The company reported a median 3.0 dose factor versus usual outpatient therapy, based on published assumptions; 84% trained independently and 84.4% asynchronously.
Statistically significant pre–post improvements were reported in independence (+10.4 points), balance (+10.5 points), cognition (+3.4 points), and mobility (−8.8 seconds).

The company expects MindMotion Lite by year-end 2026; it is designed to deliver MindMotion GO activities with reduced hardware requirements.

Investor FAQs

MindMaze Therapeutics announced new real-world evidence from a multi-site home-based rehabilitation programme conducted with Vibra Healthcare. The programme found that MindMotion increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, while 84% of active training was completed independently without direct therapist supervision.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch
Published: Wednesday, 14 October 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…